Hunan Nucien Pharmaceutical Co Ltd (688189.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100007713

Price
5.89 CNY
Market cap
1.62 bn CNY
P/E (2025)
–
P/S (2025)
11.39
Dividend yield
0.00 %
Net margin
-96.46 %
Return on equity (ROE)
-19.22 %
Return on assets (ROA)
-16.91 %

Hunan Nucien Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue251.72 m CNY141.93 m CNY
Gross profit132.17 m CNY44.71 m CNY
Operating income-76.69 m CNY-78.24 m CNY
EBIT-371.28 m CNY-129.17 m CNY
Net income-346.51 m CNY-136.90 m CNY

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Hunan Nucien Pharmaceutical Co Ltd

Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular, respiratory, and other pharmaceutical fields. Hunan Nucien Pharmaceutical Co., Ltd. was founded in 2006 and is based in Guangzhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.